New directions in natural killer cell-based immunotherapy of human cancer (Q35093608)

6 August 2017

1 reference

title

New directions in natural killer cell-based immunotherapy of human cancer (English)

1 reference

6 August 2017

1 reference

Michael A Caligiuri

1 reference

6 August 2017

Sherif S Farag

1 reference

6 August 2017

Todd A Fehniger

series ordinal

1 reference

6 August 2017

Brian Becknell

series ordinal

1 reference

6 August 2017

Bradley W Blaser

series ordinal

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

237-250

1 reference

Progress in human tumour immunology and immunotherapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

In search of the 'missing self': MHC molecules and NK cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Skin graft rejection by beta 2-microglobulin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Natural killer cell activation and inhibition by receptors for MHC class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Follow the leader: NK cell receptors for classical and nonclassical MHC class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Paired inhibitory and triggering NK cell receptors for HLA class I molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Receptors for HLA class-I molecules in human natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

HLA-G in melanoma: A new strategy to escape from immunosurveillance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

MIC genes: from genetics to biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

An activating immunoreceptor complex formed by NKG2D and DAP10

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.237

21 January 2018

Identifiers

DOI

10.1517/14712598.3.2.237

1 reference

6 August 2017

1 reference